Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs

Source: 
Fierce Biotech
snippet: 

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases.